Sponsoring Institution: Mt. Sinai Hospital
Primary Investigators:
Dr. Tony Mazzulli, Microbiologist-in-Chief for Sinai Health
Dr. Anne-Claude Gingras, Senior Investigator (molecular genetics) at Lunenfeld-Tanenbaum Research Institute
Dr. Jennifer Taher, Clinical Biochemist at Sinai Health System
Dr. Jeff Wrana, Senior Investigator (molecular genetics) at Lunenfeld-Tanenbaum Research Institute
Dr. Allison McGeer, Microbiologist, Infectious Disease Consultant, Mount Sinai Hospital
Dr. Rita Kandel, Chief of Pathology and Laboratory Medicine, Mount Sinai Hospital
Dr. Jay Wunder, Surgeon in Chief at Mount Sinai Hospital
Dr. Chaim Bell, Adjunct Scientist at the Institute for Clinical Evaluative Sciences (ICES)
Ms. Lisa Wayment, Senior Clinical Program Director Surgical Services at Sinai Health System
Dr. Janet McElhaney, Vice President of Research & Scientific Director, Health Sciences North Research Institute
SAH Site Co-Investigator:
Dr. Lucas Castellani, Medical Director Infection Prevention and Control, Sault Area Hospital
This is a study at the Mount Sinai Hospital, Sault Area Hospital and Health Sciences North (Sudbury) on a total of 1500 hospital workers (1000 from the Mount Sinai Hospital and 250 each from Sault Area Hospital and Health Science North) who have no current symptoms of COVID-19, and, if previously infected, have completely recovered from the infection. Blood will be taken from each of the volunteers and analyzed by 2 different tests (a Health Canada-approved test and a research test developed locally) to find out if antibodies to COVID-19 are present indicating a previous infection with COVID-19. This will determine how many hospital workers have been infected with COVID-19, and allow for comparison of the 2 different tests. The volunteers will also complete questionnaires which will help determine if there are different risks of infection in different types of jobs and for different ages and health status. Finally, we will study the volunteers over 18 months to see how many develop an infection later and to understand if a previous infection may prevent a re-infection.
Length of Study Participation: 18 months
| Bloodwork & Questionnaire Timepoints | |
| Study Entry | X |
| 12 weeks (3 months) | X |
| 6 months | X |
| 12 months (1 year) | X |
| 18 Months | X |
Study Start Date: February 23, 2021
Number of Participants Currently at SAH: 186
Study End Date: Closed to Enrollment